

As an educational provider accredited by the ACCME, the ACR must ensure balanced, independent, objectively and scientific rigor in all its educational activities. The 2011 ACR/ARHP Annual Scientific Meeting programs have been independently planned by the ACR Annual Meeting Planning Committee, the ARHP Annual Meeting Program Committee, and the ARHP Clinical Focus Course Task Force.

## 2011 ACR/ARHP Disclosure List

---

**Abby Abelson, MD**

*I have relevant commercial relationships to disclose.*

Amgen – consulting fees; Novartis – consulting fees

**Joan M. Bathon, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Joel A. Block, MD**

*I have relevant commercial relationships to disclose.*

Merck-Serono - consulting fees; Abbott - consulting fees

**David Borenstein, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Richard Bucala, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Robert H. Carter, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Lindsey Criswell, MD**

*I have relevant commercial relationships to disclose.*

Abbott – consulting

**Mary E. Cronin, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Atul Deodhar, MD**

*I have relevant commercial relationships to disclose.*

Centocor – research grants, consulting fees, speakers bureau; UCB – research grants; Genetech – speakers bureau; Takeda – speakers bureau

**Kori Dewing, DNP, ARNP**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Donna Everix, MPA, BS, PT**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Fernando E. Figueroa, MD**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Nadine Fisher, EdD**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Richard Furie, MD**

***I have relevant commercial relationships to disclose.***

Medical Industry related investments, including but not limited to stocks, bonds, options, or other form of investment or ownership: Pfizer; Monsanto

Clinical Investigator: BiogenIdec; BMS; Aspreva; Genentech; Hoffmann LaRoche; Human Genome Sciences; La Jolla Pharmaceuticals; Medimmune; NIAID; NovoNordisk; Rigel; UCB

Consultant: Anthera; BiogenIdec; BMS; Boehringer-Ingelheim; Cypress Bioscience; EMD Merck; Genentech; Hoffmann LaRoche; Human Genome Sciences; Idera; Medimmune; Medarex; NIAID;

NovoNordisk; Nuon; Pfizer; UCB; NIAMS; Alliance for Lupus Research

Consulting fees or other forms of remuneration (payment): HGS; Idera; NIAMS

Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson: Human Genome Sciences; American College of Rheumatology; Arthritis Foundation; LFA; Lupus Alliance of America; SLE Foundation; Alliance for Lupus Research

**Gregory Gardner, MD**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Steven R. Goldring, MD**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Yvonne M. Golightly, PT, MS, PhD**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Alexei A. Grom, MD**

***I have relevant commercial relationships to disclose.***

Novartis - consulting fees or other remuneration

**Gillian A. Hawker, MD**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Bruce I. Hoffman, MD**

***I have relevant commercial relationships to disclose.***

UCB - consulting fees

**Shelley P. Kafka, MD**

***I have relevant commercial relationships to disclose.***

Pfizer - stocks, speakers bureau and research grants; MGSI - stocks; Mylan - stocks; Geron - stocks; Centocor - consulting fees and research grants; Novartis - speakers bureau; Lilly - speakers bureau and research grants; Takeda - speakers bureau and research grants; UCB - speakers bureau; Forest - speakers bureau; Amgen - speakers bureau and research grants; Abbott - speakers bureau and research grants; BMS - speakers bureau and research grants

**Diane Kamen, MD**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Salahuddin Kazi, MD**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Sharon L. Kolasinski, MD**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Karen Kolba, MD**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Carol Langford, MD, MHS**

***I have relevant commercial relationships to disclose.***

Genentech – other; Bristol-Myers Squibb - other

**Richard F. Loeser, Jr., MD**

***I have relevant commercial relationships to disclose.***

Biomeasure inc/ISPEN – consulting fees or other remuneration

**Susan M. Maillard, MSC, SRP, MCSP**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Anne-Marie Malfait, MD, PhD**

***I have relevant commercial relationships to disclose.***

Pfizer – stocks

**Susan Manzi, MD, MPH**

***I have relevant commercial relationships to disclose.***

Human Genome Sciences - non-remunerative position of influence, research grants; Bristol-Meyers Squibb Co. - non-remunerative position of influence, research grants; Centocor, Inc. – other; Cephalon Inc. - non-remunerative position of influence, research grant; Cypress Bioscience - consulting fees; Anthera - non-remunerative position of influence; Amgen – research grant; Aspreva – research grant;

Genetech, Inc. – research grant; immunomedics – research grant; National Institutes of Health – research grant

**Kevin McKown, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Zsuzsanna McMahan, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Esi Morgan DeWitt, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Peter A. Nigrovic, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Chester V. Oddis, MD**

*I have relevant commercial relationships to disclose.*

Genetech - research grants and consulting fees; Medimmune – consulting fees

**Kathleen M. O'Neil, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Linda J. Pine, PhD**

*I have relevant commercial relationships to disclose.*

Amgen – consulting fees

**Christopher Ritchlin, MD,MPH**

*I have relevant commercial relationships to disclose.*

Amgen - research grants, consulting fees; Abbott - research grants; Centocor - research grants, consulting fees; Pfizer - consulting fees; UCB - research grants, consulting fees; Calcimedica - consulting fees

**Eric M. Ruderman, MD**

*I have relevant commercial relationships to disclose.*

Abbott - research grants, consulting fees; Amgen/Wyeth - consulting fees; Astellas - consulting fees; Biogen - consulting fees; Centocor - research grant; Celgene - consulting fees; Crescendo - research grant; Coalition of Rheumatology Researchers of North America - research grant; Lilly - consulting fees; The Rheumatology Education Group - consulting fees and ownership or partnership; Pfizer - consulting fees

**Elizabeth Salt, PhD**

*I have relevant commercial relationships to disclose.*

SmithKline Beecham – stocks

**Kenneth N. Schikler, MD**

***I have relevant commercial relationships to disclose.***

Pfizer – research grants; Abbott – research grants; Roche– research grants; Forest Laboratories – research grants; Novartis – research grants; Forest Laboratories - consulting fee; Stocks - stock holdings in mutual funds in retirement and self-directed accounts through TIAA-CREF, Fidelity and AMEX that are self-directed and contain holdings in relevant commercial interests

**Victoria K. Shanmugam, MD**

***I have relevant commercial relationships to disclose.***

Other - spouse is a partner at the law firm of Williams and Connolly LLP which represents various pharmaceutical companies and medical device companies. The partners in the firm share in the profits related to representing various pharmaceutical companies.

**Gregg Silverman, MD**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Robert Simms, MD**

***I have relevant commercial relationships to disclose.***

Actelion - research grants; United Therapeutics - research grants

**Jasvinder Singh, MD**

***I have relevant commercial relationships to disclose.***

Allergan – research grant; Takeda – research grant, consulting fees; Savient – research grant; consulting fees; URL pharmaceuticals – consulting fees; Novartis – consulting fees

**Karen L. Smarr, PhD**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Emily C. Somers, PhD, ScM**

***I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.***

**Robert Spiera, MD**

***I have relevant commercial relationships to disclose.***

Novartis - research grants; BMS - research grants; United Therapeutics - research grants

**Paul P. Tak, MD, PhD**

***I have relevant commercial relationships to disclose.***

Bristol-Meyers Squib - research grants; Pfizer – research grants, consulting fees; Abbott – research grants, consulting fees; Roche research grants, consulting fees; Novartis - research grants, consulting fees; AstraZeneca/MedImmune - research grants, consulting fees; MorphoSys - research grants, consulting fees; Chemocentryx – research grants; Johnson & Johnson – research grants; Merck Serono – research grants; ArthroGen b.v. – stocks; Setpoint – consulting fees

**George C. Tsokos, MD**

***I have relevant commercial relationships to disclose.***

Genentech – consulting fees; Lilly - consulting fees; Medimmune – consulting fees; Merck – consulting fees

**John Varga, MD**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Mary-Chester Wasko, MD, MSc**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Mary Wright, BS, OT**

*I have not had any relevant commercial relationships with any commercial interest occurring within the past twelve months.*

**Raymond L. Yung, MD**

*I have relevant commercial relationships to disclose.*

National Institutes of Health - research grant